Geron Corporation (GERN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $622.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Geron Corporation (GERN) Earnings: Report Dates and Results
Geron (GERN) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Geron reported EPS of $0.00, above the -$0.01 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GERN has an expected report date of Feb 23, 2027.
GERN Earnings Call
The latest GERN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, GERN beat 23, missed 6 and matched 11. Revenue for the quarter ended Sep 30, 2026 was $60.19M, up 27.4% from $47.23M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.00 | -$0.01 | -$0.02 - $0.00 | +120.00% | Beat | N/A | 5 | 1 up, 0 down | Nov 4, 2026 | $60.19M |
| Jun 30, 2026 | -$0.02 | -$0.01 | -$0.01 - -$0.01 | -100.00% | Miss | N/A | 2 | 0 up, 0 down | Aug 5, 2026 | $57.48M |
| Mar 31, 2026 | $0.00 | -$0.02 | -$0.02 - -$0.02 | +75.50% | Beat | N/A | 2 | 0 up, 0 down | May 6, 2026 | $51.84M |
| Dec 31, 2025 | -$0.02 | -$0.03 | N/A | +24.29% | Beat | N/A | 2 | 0 up, 2 down | Feb 25, 2026 | $48.02M |
| Sep 30, 2025 | -$0.03 | -$0.03 | -$0.05 - -$0.03 | 0.00% | In line | N/A | 3 | 0 up, 1 down | Nov 5, 2025 | $47.23M |
| Jun 30, 2025 | -$0.02 | -$0.03 | -$0.04 - -$0.01 | +33.33% | Beat | N/A | 5 | 0 up, 1 down | Aug 6, 2025 | $49.04M |
| Mar 31, 2025 | -$0.03 | -$0.04 | -$0.04 - -$0.03 | +25.00% | Beat | N/A | 3 | 1 up, 1 down | May 7, 2025 | $39.60M |
| Dec 31, 2024 | -$0.04 | -$0.05 | -$0.06 - -$0.03 | +23.28% | Beat | N/A | 5 | 0 up, 1 down | Feb 26, 2025 | $47.54M |
| Sep 30, 2024 | -$0.04 | -$0.08 | -$0.10 - -$0.08 | +50.00% | Beat | N/A | 10 | 0 up, 0 down | Nov 7, 2024 | $28.27M |
| Jun 30, 2024 | -$0.10 | -$0.10 | -$0.11 - -$0.10 | 0.00% | In line | N/A | 7 | 0 up, 0 down | Aug 8, 2024 | $882000 |
| Mar 31, 2024 | -$0.09 | -$0.09 | -$0.10 - -$0.09 | 0.00% | In line | N/A | 7 | 0 up, 0 down | May 2, 2024 | $304000 |
| Dec 31, 2023 | -$0.09 | -$0.10 | -$0.12 - -$0.09 | +10.00% | Beat | N/A | 6 | 0 up, 0 down | Feb 28, 2024 | N/A |
| Sep 30, 2023 | -$0.08 | -$0.10 | -$0.12 - -$0.09 | +20.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 2, 2023 | $164000 |
| Jun 30, 2023 | -$0.09 | -$0.08 | -$0.11 - -$0.07 | -12.50% | Miss | N/A | 6 | 0 up, 0 down | Aug 3, 2023 | $29000 |
| Mar 31, 2023 | -$0.07 | -$0.10 | -$0.12 - -$0.09 | +30.00% | Beat | N/A | 6 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.10 | -$0.12 | -$0.15 - -$0.10 | +16.67% | Beat | N/A | 6 | 0 up, 0 down | Mar 16, 2023 | N/A |
| Sep 30, 2022 | -$0.10 | -$0.09 | -$0.11 - -$0.08 | -11.11% | Miss | N/A | 6 | 0 up, 0 down | Nov 3, 2022 | $297000 |
| Jun 30, 2022 | -$0.07 | -$0.09 | -$0.10 - -$0.09 | +22.22% | Beat | N/A | 5 | 0 up, 0 down | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$0.09 | -$0.10 | -$0.11 - -$0.10 | +10.00% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2022 | $123000 |
| Dec 31, 2021 | -$0.10 | -$0.08 | -$0.09 - -$0.08 | -25.00% | Miss | N/A | 5 | 0 up, 0 down | Mar 10, 2022 | $1.15M |
| Sep 30, 2021 | -$0.08 | -$0.09 | -$0.10 - -$0.08 | +11.11% | Beat | N/A | 5 | 1 up, 0 down | Nov 9, 2021 | N/A |
| Jun 30, 2021 | -$0.09 | -$0.09 | -$0.10 - -$0.08 | 0.00% | In line | N/A | 5 | N/A | Aug 16, 2021 | $107000 |
| Mar 31, 2021 | -$0.09 | -$0.08 | -$0.08 - -$0.08 | -12.50% | Miss | N/A | 5 | N/A | May 10, 2021 | $137000 |
| Dec 31, 2020 | -$0.07 | -$0.06 | -$0.07 - -$0.06 | -16.67% | Miss | N/A | 6 | N/A | Mar 11, 2021 | $50000 |
| Sep 30, 2020 | -$0.06 | -$0.06 | -$0.06 - -$0.05 | 0.00% | In line | N/A | 6 | N/A | Nov 5, 2020 | $108000 |
| Jun 30, 2020 | -$0.06 | -$0.06 | -$0.07 - -$0.05 | 0.00% | In line | N/A | 5 | N/A | Aug 6, 2020 | $43000 |
| Mar 31, 2020 | -$0.08 | -$0.12 | -$0.17 - -$0.09 | +33.33% | Beat | N/A | 4 | N/A | May 28, 2020 | $52000 |
| Dec 31, 2019 | -$0.15 | -$0.19 | -$0.22 - -$0.19 | +21.05% | Beat | N/A | 5 | N/A | Mar 12, 2020 | $171000 |
| Sep 30, 2019 | -$0.08 | -$0.13 | -$0.20 - -$0.13 | +38.46% | Beat | N/A | 4 | N/A | Nov 6, 2019 | $131000 |
| Jun 30, 2019 | -$0.08 | -$0.10 | -$0.11 - -$0.06 | +20.00% | Beat | N/A | 3 | N/A | Aug 1, 2019 | $101000 |
| Mar 31, 2019 | -$0.05 | -$0.05 | -$0.09 - -$0.05 | 0.00% | In line | N/A | 2 | N/A | May 2, 2019 | $57000 |
| Dec 31, 2018 | -$0.04 | -$0.04 | -$0.05 - -$0.04 | 0.00% | In line | N/A | 3 | N/A | Mar 7, 2019 | $375000 |
| Sep 30, 2018 | -$0.03 | -$0.05 | -$0.05 - -$0.05 | +40.00% | Beat | N/A | 2 | N/A | Nov 1, 2018 | $165000 |
| Jun 30, 2018 | -$0.04 | -$0.04 | -$0.04 - -$0.04 | 0.00% | In line | N/A | 2 | N/A | Jul 31, 2018 | $208000 |
| Mar 31, 2018 | -$0.04 | -$0.05 | N/A | +20.00% | Beat | N/A | N/A | N/A | May 10, 2018 | $318000 |
| Dec 31, 2017 | -$0.05 | -$0.05 | -$0.05 - -$0.04 | 0.00% | In line | N/A | 3 | N/A | Mar 16, 2018 | $191000 |
| Sep 30, 2017 | -$0.04 | -$0.05 | -$0.06 - -$0.04 | +20.00% | Beat | N/A | 3 | N/A | Nov 1, 2017 | $163000 |
| Jun 30, 2017 | -$0.04 | -$0.05 | -$0.05 - -$0.05 | +20.00% | Beat | N/A | 3 | N/A | Aug 9, 2017 | $174000 |
| Mar 31, 2017 | -$0.05 | -$0.05 | N/A | 0.00% | In line | N/A | N/A | N/A | May 9, 2017 | $537000 |
| Dec 31, 2016 | -$0.05 | -$0.06 | N/A | +16.67% | Beat | N/A | N/A | N/A | Mar 1, 2017 | $94000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.10, after -$0.27 the year before. It was -$0.18 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.10 | N/A |
| Dec 31, 2024 | -$0.27 | N/A |
| Dec 31, 2023 | -$0.33 | N/A |
| Dec 31, 2022 | -$0.36 | N/A |
| Dec 31, 2021 | -$0.36 | N/A |
| Dec 31, 2020 | -$0.27 | N/A |
| Dec 31, 2019 | -$0.36 | N/A |
| Dec 31, 2018 | -$0.15 | N/A |
| Dec 31, 2017 | -$0.18 | N/A |
| Dec 31, 2016 | -$0.18 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,600 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,620 | 9 | |
| 2026Q2 | Jun 30, 2026 | 3,724 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,056 | 11 | |
| 2025Q4 | Dec 31, 2025 | 4,064 | 11 | |
| 2025Q3 | Sep 30, 2025 | 5,302 | 11 | |
| 2025Q2 | Jun 30, 2025 | 5,543 | 15 | |
| 2025Q1 | Mar 31, 2025 | 7,161 | 14 | |
| 2024Q4 | Dec 31, 2024 | 6,758 | 15 |
2026Q3 Earnings Call
Opening remarks
Dawn Schottlandt SVP, Investor Relations and Corporate Affairs Good morning, everyone. Welcome to the Geron Corporation Third Quarter 2026 Earnings Conference Call. Before we begin, please note that during the course of the presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations and other projections, including those related to our 2026 financial guidance, our current RYTELO commercialization strategy and related opportunities in the U.S. and the EU, the therapeutic potential of RYTELO, other anticipated clinical and commercial events and related timelines, the sufficiency of our financial resources, and other statements that are not historical fact. These statements, of course, involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements. Therefore, I refer you to the risks and uncertainties described in today's earnings release under the heading Risk Factors and in Geron's most recent periodic report filed with the SEC, which identify important factors that could cause actual results to differ materially from those contained in these forward-looking statements, as well as future updates to Geron's risk and uncertainty disclosures, including in its upcoming quarterly report on Form 10-Q. Geron undertakes no duty or obligation to update its forward-looking statements. Joining me on today's call are several members of Geron's management team: Harout Semerjian, Chief Executive Officer; Ahmed ElNawawi, our Chief Commercial Officer; Dr. Joseph Eid, Executive Vice President, Research and Development and Chief Medical Officer; and Michelle Robertson, our Chief Financial Officer. With that, I'll turn the call over to Harout to discuss Geron's progress in the third quarter.
Harout Semerjian CEO Thank you, Dawn, and good morning, everyone. We continue to execute our strategy to build a leading hematology company. We're delivering consistent RYTELO demand growth, reinforcing our confidence in the low-risk MDS U.S. commercial opportunity and RYTELO's growth trajectory over the next several years. We also initiated a gated commercial launch in targeted European markets that gives us the optionality to scale up RYTELO's availability through partnerships. Last week, we announced the discontinuation of the IMpactMF trial evaluating imetelstat in relapsed and refractory myelofibrosis following a recommendation by the independent DMC. We believe this is the right course of action for patients and for Geron. In the third quarter, we continued to see increased prescribing from community practices, leading to quarter-over-quarter demand growth of 10% and net revenue growth of 5%, to $60.1 million. This represents a 27% increase in net revenue year over year. This performance keeps us on track to achieve the mid- to high end of our full-year 2026 net revenue guidance range of $220 million to $240 million and reinforces our confidence that RYTELO has a long growth runway in the U.S.
Frequently Asked Questions About GERN
When is Geron's next earnings date?
Geron's next earnings report is expected for Feb 23, 2027.
Did GERN beat earnings estimates last quarter?
Yes. Geron reported EPS of $0.00 for the quarter ended Sep 30, 2026, above the -$0.01 estimate, a 120.00% surprise.
What EPS do analysts expect from GERN next quarter?
The consensus EPS estimate for Geron for the quarter ending Dec 31, 2026 is $0.00 from 7 analysts, with estimates from -$0.01 to $0.02.
How often does GERN beat earnings estimates?
Geron beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +25.17%.
GERN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors